MCRPC: SRE rates top 34% in PREVAIL and AFFIRM studies

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Over a third of patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL and AFFIRM trials experienced skeletal-related events (SREs). 
  • First SREs was significantly associated with functional decline and reduced health-related QoL (HRQoL). 
  • Spinal cord comp...